You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Baxter
Express Scripts
Medtronic

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Patent: 7,888,489

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,888,489
Title:Method for producing a compound of interest in a filamentous fungal cell
Abstract: The invention relates to a nucleotide sequence comprising; a synonymous nucleotide coding sequence with optimized codon frequency such that a native codon has been exchanged with a synonymous codon, the synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon; and optionally the nucleotide sequence comprises control sequences such as; one translational termination sequence orientated in 5\' towards 3\' direction selected from the following list of sequences; TAAG, TAGA and TAAA, preferably TAAA, and/or one translational initiator coding sequence orientated in 5\' towards 3\' direction selected from the following list of sequences; gctnccyyc (SEQ ID NO:20), using ambiguity codes for nucleotides; v (A/C/G); n (A/C/G/T), preferably 5\'-GCT TCC TTC-3\' (SEQ ID NO:21). The invention further relates to a consensus translational initiator sequence; 5\'-mwChkyCAmv-3\' (SEQ ID NO:16), preferably the translational initiator sequence is selected from the list consisting of; 5\'-mwChkyCAAA-3\' (SEQ ID NO:17), 5\'-mwChkyCACA-3\' (SEQ ID NO:18), and 5\'-mwChkyCAAG-3\' (SEQ ID NO:19).
Inventor(s): Roubos; Johannes Andries (Pijnacker, NL), Donkers; Serge Petrus (Hellevoetsluis, NL), Stam; Hein (Huizen, NL), Peij; Noel Nicolaas Maria Elisabeth Van (Delft, NL)
Assignee: DSM IP Assets B.V. (Heerlen, NL)
Application Number:11/795,824
Patent Claims:see list of patent claims

Details for Patent 7,888,489

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial DSM IP Assets B.V. (Heerlen, NL) 2025-01-24 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial DSM IP Assets B.V. (Heerlen, NL) 2025-01-24 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial DSM IP Assets B.V. (Heerlen, NL) 2025-01-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Medtronic
Dow
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.